As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.
6 Analysts have issued a Minerva Neurosciences Inc forecast:
6 Analysts have issued a Minerva Neurosciences Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -15 -15 |
40%
40%
|
|
| EBIT (Operating Income) EBIT | -15 -15 |
40%
40%
|
|
| Net Profit | -14 -14 |
324%
324%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | Rémy Luthringer |
| Employees | 8 |
| Founded | 2007 |
| Website | www.minervaneurosciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


